EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

HERACLIS_BLV_D: Adherence to Real‐Life Therapy With Bulevirtide in Chronic Hepatitis D

Dimitra Lakiotaki, Margarita Papatheodoridi, Vasilios Sevastianos, Kalliopi Zachou, Dimitrios Christodoulou, John Koskinas, Melanie Deutsch, Alexandra Alexopoulou, Ioannis Elefsiniotis iD, Christos Triantos, Elena Gigi, Theodoros Androutsakos iD und 27 weitere

Journal of Viral Hepatitis · 2026-07 · 33 (7)

DOI: 10.1111/jvh.70201 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 19.06.2026. Verfasst von Dimitra Lakiotaki und 38 weiteren Autor:innen. Beteiligte Einrichtung: General Hospital of Athens "Laiko", Medical School of National & Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Monitoring, Hepatitis D, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daily subcutaneous bulevirtide (BLV) 2 mg has been approved as first‐line treatment for chronic hepatitis D (CHD), but long‐term real‐world adherence data are limited. We assessed adherence rates during BLV therapy and their impact on treatment response. HERACLIS_BLV_D study (NCT05928000) included adult CHD patients initiating BLV 2 mg/day and followed in routine clinical practice. Virological response (VR) was defined as HDV RNA < 57.5 IU/mL or decline > 2 log 10 and biochemical response (BR) as normal ALT (≤ 40 IU/L). Adherence was evaluated through the national prescription system based on executed monthly BLV prescriptions. Treatment discontinuation was defined as no executed BLV prescription for > 3 months at the end of follow‐up. Seventy‐six patients were included. VR/BR rates were 73%/71% at 12 and 93%/74% at 24 months. Thirteen (17%) patients discontinued BLV (none due to adverse events); 6%–7% per year. Mean adherence among treated patients was 98% ± 6% in 1st year declining to 93% ± 13% in 2nd and 91% ± 17% in 3rd year ( p ≤ 0.010). No baseline characteristic was associated with poor (< 90%) or good (≥ 90%) adherence to BLV therapy. Patients with poor vs. good adherence had lower VR rates (1st year: 33% vs. 77%, p = 0.038; 2nd year: 60% vs. 97%, p = 0.030). In conclusion, in clinical practice, < 10% of CHD patients discontinue BLV therapy annually. Adherence is excellent in the first year and remains > 90% until the third year although gradually declines. Poor (< 90%) adherence cannot be predicted but adversely affects the VR rates emphasizing the need for strategies to support long‐term treatment retention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDrug MonitoringHepatitis D, ChronicAdultAgedFemaleHumansMaleMiddle AgedRNA, ViralTreatment OutcomeViral LoadLipopeptides

Stichwörter der Autor:innen

adherencebulevirtidechronic hepatitis Dreal‐world study

Substanzen

Antiviral AgentsbulevirtideRNA, ViralLipopeptides

Autor:innen und Institutionen

  • General Hospital of Athens "Laiko", Medical School of National & Kapodistrian University of Athens, Athens, Greece.
  • General Hospital of Athens "Evangelismos", Athens, Greece.
  • General University Hospital of Larissa, Larissa, Greece.
  • University General Hospital of Ioannina, Ioannina, Greece.
  • General Hospital of Athens "Hippokratio", Medical School of National and Kapodistrian University of Athens, Athens, Greece.
  • General and Oncology Hospital of Kifisia "Agioi Anargyroi", Athens, Greece.

ORCID-Profile: Ioannis Elefsiniotis, Theodoros Androutsakos, Iliana Mani, Emmanouil Sinakos, John Vlachogiannakos, George Papatheodoridis

Förderung

  • Gilead Sciences

Zitieren

APA

Lakiotaki, D., Papatheodoridi, M., Sevastianos, V., Zachou, K., Christodoulou, D., Koskinas, J., Deutsch, M., Alexopoulou, A., Elefsiniotis, I., Triantos, C., Gigi, E., Androutsakos, T., Karagiannakis, D. S., Mani, I., Dimitroulopoulos, D., Mela, M., Sinakos, E., Michopoulos, S., Mimidis, K., …, & Papatheodoridis, G. (2026). HERACLIS_BLV_D: Adherence to Real‐Life Therapy With Bulevirtide in Chronic Hepatitis D. Journal of Viral Hepatitis, 33(7). https://doi.org/10.1111/jvh.70201

Vancouver

Lakiotaki D, Papatheodoridi M, Sevastianos V, Zachou K, Christodoulou D, Koskinas J, et al. HERACLIS_BLV_D: Adherence to Real‐Life Therapy With Bulevirtide in Chronic Hepatitis D. Journal of Viral Hepatitis. 2026;33(7). doi:10.1111/jvh.70201

BibTeX
@article{Lakiotaki2026,
  author = {Lakiotaki, Dimitra and Papatheodoridi, Margarita and Sevastianos, Vasilios and Zachou, Kalliopi and Christodoulou, Dimitrios and Koskinas, John and Deutsch, Melanie and Alexopoulou, Alexandra and Elefsiniotis, Ioannis and Triantos, Christos and Gigi, Elena and Androutsakos, Theodoros and Karagiannakis, Dimitrios S and Mani, Iliana and Dimitroulopoulos, Dimitrios and Mela, Maria and Sinakos, Emmanouil and Michopoulos, Spyros and Mimidis, Konstantinos and Papadopoulos, Nikolaos and Kontos, Athanasios and Veretanos, Christos and Lymperopoulos, Dimitrios and Giannoulis, George and Papadimitropoulos, Vasilios and Avramopoulou, Evdoxia and Papatheodoridi, Alkistis and Pantzios, Spyridon and Vasilieva, Larisa and Kranidioti, Hariklia and Koullias, Emmanouil and Soukovelos, Athanasios and Fytili, Paraskevi and Vlachogiannakos, John and Cholongitas, Evangelos and Manolakopoulos, Spilios and Goulis, Ioannis and Dalekos, George and Papatheodoridis, George},
  title = {HERACLIS_BLV_D: Adherence to Real‐Life Therapy With Bulevirtide in Chronic Hepatitis D},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1111/jvh.70201}
}
Kostenlos starten →